Stcube saw no growth in patent filings and highest growth of 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Stcube’s patent filings and grants. Buy the databook here.
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Stcube has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 100% filings and 33% grants. The Australia(AU), and United States(US) patent Office are among the top ten patent offices where Stcube is filings its patents. Among the top granted patent authorities, Stcube has 67% of its grants in United States(US) and 33% in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Stcube
Patents related to rare diseases lead Stcube's portfolio
Stcube has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Breast cancer related patents lead Stcube portfolio followed by cervical cancer, and testicular cancer
Stcube has highest number of patents in breast cancer followed by cervical cancer, testicular cancer, head and neck cancer, and colon cancer.
For comprehensive analysis of Stcube's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

